A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.

Autor: Conduit C; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia., Davis ID; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.; Eastern Health, Melbourne, VIC, Australia., Goh JC; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Royal Brisbane and Women's Hospital, Herston, QLD, Australia., Kichenadasse G; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, SA, Australia., Gurney H; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Macquarie University, Sydney, NSW, Australia., Harris CA; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; St George Hospital Cancer Care Centre, Kogarah, NSW, Australia.; University of NSW South Wales, Sydney, NSW, Australia., Pook D; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Monash Health, Melbourne, VIC, Australia., Krieger L; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; GenesisCare North Shore, St Leonards, NSW, Australia., Parnis F; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Adelaide Cancer Centre, Kurralta Park, SA, Australia., Underhill C; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre, East Albury, NSW, Australia.; Rural Medical School, Albury Campus, University of New South Wales, Albury-Wodonga, NSW, Australia., Adams D; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Macarthur Cancer Therapy Centre, Campbelltown, NSW, Australia., Roncolato F; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Macarthur Cancer Therapy Centre, Campbelltown, NSW, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia., Joshua A; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia., Ferguson T; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Fiona Stanley Hospital, Perth, WA, Australia., Prithviraj P; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Ballarat Oncology and Haematology Services, Ballarat, VIC, Australia., Morris M; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Sunshine Coast University Hospital, Birtinya, QLD, Australia., Harrison M; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Hunters Hill, NSW, Australia., Begbie S; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; North Coast Cancer Institute, Port Macquarie Base Hospital, Port Macquarie, NSW, Australia., Hovey E; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Randwick, Sydney, NSW, Australia.; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia., George M; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Northwest Cancer Centre, Tamworth Hospital, Tamworth, NSW, Australia., Liow EC; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Monash Health, Melbourne, VIC, Australia., Link EK; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Centre for Biostatistics and Clinical Trials (BaCT), Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, VIC, Australia., McJannett M; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia., Gedye C; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.; Calvary Mater Newcastle, Waratah, NSW, Australia.

Publikováno v: BJU international [BJU Int] 2024 Feb; Vol. 133 Suppl 3, pp. 57-67. Date of Electronic Publication: 2023 Nov 20.

Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations.

Autor: Conduit C; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia., Lewin J; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; ONTrac at Peter Mac, Victorian Adolescent and Young Adult Cancer Service, Melbourne, VIC, Australia., Weickhardt A; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.; La Trobe University, Melbourne, VIC, Australia.; Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia., Lynam J; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia.; University of Newcastle, Callaghan, NSW, Australia., Wong S; Department of Medical Oncology, Western Health, Footscray, VIC, Australia., Grimison P; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.; University of Sydney, Camperdown, NSW, Australia., Sengupta S; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Department of Urology, Eastern Health, Box Hill, VIC, Australia., Pranavan G; Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia., Parnis F; Department of Medical Oncology, Icon Cancer Centre, Adelaide, SA, Australia., Bastick P; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Southside Cancer Care Centre, Kogarah, NSW, Australia.; Department of Medical Oncology, St George/Sutherland Hospital, Caringbah, NSW, Australia., Campbell D; Department of Medical Oncology, Barwon Health, Geelong, VIC, Australia., Hansen AR; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Department of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.; University of Queensland, Brisbane, QLD, Australia., Leonard M; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia., McJannett M; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia., Stockler MR; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.; University of Sydney, Camperdown, NSW, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.; Department of Medical Oncology, Concord Repatriation General Hospital, Concord, NSW, Australia., Gibbs P; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Department of Medical Oncology, Western Health, Footscray, VIC, Australia., Toner G; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia., Davis ID; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; Monash University Eastern Health Clinical School, Box Hill, VIC, Australia.; Department of Medical Oncology, Eastern Health, Box Hill, VIC, Australia., Tran B; Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia., Kuchel A; The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.; University of Queensland, Brisbane, QLD, Australia.; Department of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.

Publikováno v: JCO oncology practice [JCO Oncol Pract] 2023 Nov; Vol. 19 (11), pp. 973-980. Date of Electronic Publication: 2023 Jun 16.

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

Autor: Saad F; Centre Hospitalier de l'Université de Montréal, Montreal, Canada. Electronic address: fred.saad@umontreal.ca., Clarke NW; The Christie and Salford Royal Hospital NHS Foundation Trusts and University of Manchester, Manchester, UK. Electronic address: noel.clarke@nca.nhs.uk., Oya M; Keio University School of Medicine, Tokyo, Japan., Shore N; Carolina Urologic Research Center, Myrtle Beach, SC, USA., Procopio G; Programma Prostata Fondazione Istituto Nazionale Tumori Milano, Milan, Italy., Guedes JD; Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil., Arslan C; Izmir Economy University Medical Point Hospital, Karsiyaka, Izmir, Turkey., Mehra N; Radboud Universitair Medisch Centrum, Nijmegen, Netherlands., Parnis F; Ashford Cancer Centre Research, Adelaide, Australia., Brown E; University Hospital Southampton, Southampton, UK., Schlürmann F; CHI de Cornouaille, Quimper, France., Joung JY; National Cancer Center, Goyang, South Korea., Sugimoto M; Kagawa University Hospital, Kagawa, Japan., Sartor O; Mayo Clinic, Rochester, MN, USA., Liu YZ; Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, UK., Poehlein C; Merck & Co, Rahway, NJ, USA., Barker L; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK., Del Rosario PM; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, UK., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Oct; Vol. 24 (10), pp. 1094-1108. Date of Electronic Publication: 2023 Sep 12.

Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023].

Autor: Ernst MS; Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Navani V; Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Wells JC; Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Donskov F; Department of Oncology, Aarhus University Hospital & University Hospital of Southern Denmark, Esbjerg, Denmark., Basappa N; Cross Cancer Clinic, University of Alberta, Edmonton, Alberta, Canada., Labaki C; Dana-Farber Cancer Institute, Boston, MA, USA., Pal SK; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Meza L; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Wood LA; Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada., Ernst DS; London Regional Cancer Centre, London, Ontario, Canada., Szabados B; Barts Cancer Institute, Queen Mary University of London, London, UK., McKay RR; University of California San Diego, Moores Cancer Center, San Diego, CA, USA., Parnis F; Icon Cancer Centre, Adelaide, South Australia, Australia., Suarez C; Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain., Yuasa T; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Lalani AK; Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada., Alva A; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Bjarnason GA; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA., Heng DYC; Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. Electronic address: Daniel.Heng@AHS.ca.

Publikováno v: European urology [Eur Urol] 2023 Jun; Vol. 83 (6), pp. e166-e167. Date of Electronic Publication: 2023 Mar 25.

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.

Autor: Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, SA, Australia. Electronic address: christopher.sweeney@adelaide.edu.au., Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW, Australia; Chris O'Brien Lifehouse, Sydney, NSW Australia., Begbie S; Port Macquarie Base Hospital, Port Macquarie, NSW, Australia; Mid North Coast Cancer Institute, Port Macquarie, NSW, Australia., Cheung L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Chi KN; BC Cancer, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada., Chowdhury S; Guys and St Thomas' NHS Foundation Trust, Biomedical Research Centre, Cancer Research UK, King's College London, UK; Sarah Cannon Research Institute, London, UK., Frydenberg M; Monash University, Melbourne, VIC, Australia; Australian Urology Associates, Melbourne, VIC, Australia., Horvath LG; Chris O'Brien Lifehouse, Sydney, NSW Australia; University of Sydney, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Joshua AM; Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia., Lawrence NJ; Te Whatu Ora, Te Toka Tumai Auckland, Auckland, New Zealand; Department of Oncology, The University of Auckland, New Zealand., Marx G; Sydney Adventist Hospital, Sydney, NSW, Australia; Australian National University, Canberra, ACT, Australia., McCaffrey J; Cancer Trials Ireland, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland., McDermott R; Cancer Trials Ireland, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; University College Dublin, Dublin, Ireland., McJannett M; Australian and New Zealand Urogenital and Prostate Cancer Trials Cancer Trials Group, Camperdown, NSW, Australia., North SA; Cross Cancer Institute, Edmonton, AB, Canada; University of Alberta, Edmonton, AB, Canada., Parnis F; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia; Icon Cancer Centre, Adelaide, SA, Australia., Parulekar W; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada., Pook DW; Monash University, Melbourne, VIC, Australia; Monash Health, Melbourne, VIC, Australia., Reaume MN; University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada., Sandhu SK; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia., Tan A; Te Whatu Ora Waikato, Hamilton, New Zealand., Tan TH; Royal Adelaide Hospital, Adelaide, SA, Australia., Thomson A; Royal Cornwall Hospital, Truro, UK., Vera-Badillo F; Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada; Kingston Health Sciences Center, Kingston, ON, Canada., Williams SG; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; University of Melbourne, Melbourne, VIC, Australia., Winter D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Yip S; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia., Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Chris O'Brien Lifehouse, Sydney, NSW Australia; Macquarie University, Sydney, NSW, Australia., Zielinski RR; Orange Health Service, Central West Cancer Care Centre, Orange, NSW, Australia; Western Sydney University, Sydney, NSW, Australia., Davis ID; Monash University, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Apr; Vol. 24 (4), pp. 323-334.